Phases précoces tumeurs solides
BET115521
A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with NUT midline carcinoma(NMC) and other cancers.
Paris
CHRISTOPHE LE TOURNEAU
Phases précoces tumeurs solides
CA009-002 (Immuno)
A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy;of anti-GITR Monoclonal Antibody (BMS-986156) Administered Alone and in Combination;with Nivolumab (BMS-936558, anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors
Paris
EMANUELA ROMANO
Phases précoces tumeurs solides
CA017-003
A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors.
Paris
CHRISTOPHE LE TOURNEAU
Gynécologie - Endomètre
ENDOLA
A Phase I/II Trial to Assess the Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Recurrent Advanced/Metastatic Endometrial Cancer Patients
Paris
MANUEL RODRIGUES
Mélanome uvéal et tumeurs oculaires
IMCgp100-202
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Paris
Appareil Digestif
SCARCE (C17-02 PRODIGE 60)
A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma
Paris
Recherches "plusieurs pathologies"
NIPINEC (GCO-001)
A GCO Trial Exploring the Efficacy and Safety of Nivolumab Monotherapy or Nivolumab Plus Ipilimumab in Pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)
Paris
NICOLAS GIRARD
Recherches "plusieurs pathologies"
CA209-848
A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Paris
EMANUELA ROMANO
Appareil Digestif
SAMCO (FFCD1603-PRODIGE 54)
Multicenter Randomized Phase II Study Comparing the Effectiveness and Tolerance of Avelumab Versus Standard 2nd Line Treatment Chemotherapy in Patients With Colorectal Metastatic Cancer With Microsatellite Instability (MSI).
Paris
BRUNO BUECHER